oxytocin
Enable an agent to recognise oxytocin, assess its molecular and functional state, and determine which handling, research or therapeutic actions require further evidence or authorisation.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise oxytocin, assess its molecular and functional state, and determine which handling, research or therapeutic actions require further evidence or authorisation.
Oxytocin is a cyclic nonapeptide hormone synthesized chiefly by hypothalamic neurons that promotes uterine contraction and milk ejection and also acts as a signaling molecule within the brain.
It can be Match a substance record or sample to oxytocin using structural and analytical evidence.; Compare concentration and potency results after checking matrix, units, assay and reference standard.; Trace endogenous processing or manufactured lot provenance and identify missing evidence.; Assess whether documented storage and quality results support continued use for a stated purpose.; Evaluate receptor and physiological claims within their species, compartment and experimental context.; Route a proposed use to the relevant research, medicinal-product or clinical model when additional controls apply..
Distinguishing features
Identify the mature nonapeptide with sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly, a Cys1-Cys6 disulfide bridge and an amidated C terminus; sequence alone does not establish correct stereochemistry or conformation.
Distinguish mature oxytocin from its precursor and associated neurophysin using molecular identity and processing evidence.
Distinguish oxytocin from vasopressin and modified analogues through sequence and structural analysis; related receptor activity is insufficient identification.
Distinguish the oxytocin component from a medicine or laboratory preparation containing buffers, preservatives, counterions or other substances.
Treat endogenous and synthetic origin as provenance differences rather than separate molecular identities when structural equivalence is demonstrated.
Scope
+ Molecular identity, peptide sequence, stereochemistry and disulfide connectivity
+ Endogenous or manufactured provenance and relationships to precursor processing
+ Oxytocin receptor activity and context-dependent biological effects
+ Sample composition, concentration, potency, degradation and storage state
+ Substance identifiers, grade and evidence governing permissible use
- Complete anatomy and function of hypothalamic, pituitary, reproductive or mammary systems
- Finished medicinal product formulations, packaging and marketing authorisations
- Patient-specific prescribing, dosing and obstetric management
- Manufacturing equipment and complete synthesis processes
- Independent models of vasopressin, oxytocin analogues and receptor proteins
- General theories of attachment, trust or social behaviour
Characteristics
- Molecular identity
- Sequence, residue stereochemistry, terminal modifications and disulfide connectivity Separates mature oxytocin from precursors, analogues and structurally altered material.
- Chemical registry identity
- Verified CAS, PubChem and applicable EC records, with represented chemical form Supports cross-source matching without conflating the peptide with salts or preparations.
- Origin and processing
- Endogenous, chemically synthesised, other documented production route or unknown Determines which processing, impurity and traceability evidence is relevant.
- Biological location
- Species, tissue, cellular or extracellular compartment, and sampling time Prevents measurements from different biological compartments being treated as interchangeable.
- Amount or concentration
- mol, mg, mol/L or mass/volume, with matrix, method and uncertainty Makes quantities interpretable and distinguishes substance amount from activity.
- Biological potency
- Assay-defined activity or IU per stated amount or volume, with reference standard Prevents an unsupported conversion between peptide mass and functional activity.
- Purity and impurity profile
- Method-specific purity percentage and identified impurity concentrations Determines whether reported material represents intact oxytocin adequately for its intended use.
- Physical and stability state
- Dry or dissolved form; temperature, pH where applicable, exposure history and degradation assessment Connects handling conditions to evidence of retained identity and activity.
- Receptor response
- Assay-specific binding or response parameters, with receptor, species and experimental conditions Separates measured receptor engagement from inferred whole-organism effects.
- Grade and use eligibility
- Documented grade, applicable specification, jurisdiction and permitted-use status Prevents research material or unverified samples from being treated as eligible for clinical use.
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 34 questions.
Peptide identity Establishes which molecular entity an oxytocin record or sample represents.
Related peptides, precursors and preparations cannot be distinguished reliably by name or biological activity alone.
Mature molecule
Records the structural features required to identify mature oxytocin.
Structural identity evidence
Requires evidence for sequence, stereochemistry, terminal amidation and disulfide connectivity.
- Which analytical evidence confirms the expected sequence, stereochemistry, C-terminal amidation and Cys1-Cys6 disulfide connectivity? measurement
- Does the material contain mature oxytocin, precursor material, an analogue or a mixture of these? boundary
Registered form
Connects identifiers to the exact peptide form and separates it from its surrounding preparation.
Identifier and form alignment
Checks whether identifiers and reported quantities refer to oxytocin itself or to a salt, hydrated material or formulated preparation.
- Which verified chemical identifiers describe the represented oxytocin form? provenance
- Are counterions, water and excipients included in the reported mass or modelled separately? boundary
Origin and biological location Describes how oxytocin arose and where a biological observation applies.
Molecular equivalence does not make production histories or measurements from different biological compartments equivalent.
Production and processing
Distinguishes endogenous precursor processing from manufactured production.
Origin traceability
Connects mature peptide to documented biological processing or a manufactured lot.
- What evidence establishes endogenous origin or the production route and lot of manufactured oxytocin? provenance
- For endogenous material, which precursor and processing evidence supports identification of the mature peptide? definition
Compartment and sampling
Anchors biological measurements to species, location, timing and sample treatment.
Biological measurement context
Records the context needed to interpret an oxytocin measurement without extending it to unmeasured compartments.
- Which species, tissue or fluid, sampling time and physiological context does the measurement represent? measurement
- What evidence supports any proposed inference from the sampled compartment to central or other unmeasured oxytocin activity? boundary
- How were collection, extraction and sample preservation validated for the measurement method? provenance
Receptor activity and effects Connects oxytocin exposure to measured receptor responses and bounded physiological claims.
Chemical identity, receptor activity and whole-organism outcomes are different kinds of evidence.
Receptor engagement
Records binding and functional responses in a specified receptor system.
Assay-specific response
Qualifies activity claims by receptor identity, species, concentration and assay endpoint.
- Which receptor, species, expression system and endpoint were used to measure oxytocin activity? measurement
- What concentration-response and comparator evidence distinguishes oxytocin receptor activity from activity at related receptors? measurement
Physiological interpretation
Separates measured tissue or organism responses from broader causal interpretations.
Effect and context
Requires contextual evidence for claims concerning uterine activity, milk ejection or behavioural outcomes.
- Which effect was measured directly, and under what reproductive state, exposure route and timing? measurement
- Does the evidence establish causation, association or only a proposed mechanism for the claimed outcome? boundary
- Which population or experimental limits prevent generalising the result to other physiological or social contexts? boundary
Sample quality and stability Assesses how much intact, active oxytocin a sample contains and whether that state has been maintained.
A label or nominal concentration does not establish peptide integrity, potency or suitability after handling.
Content, purity and potency
Separates chemical amount, analytical purity and biological activity.
Quantitative quality evidence
Links each quality result to its method, matrix, reference standard and uncertainty.
- What methods quantify intact oxytocin and distinguish it from related peptides or degradation products? measurement
- Which reference standard supports the potency value and any conversion between mass and international units? provenance
- Which impurity limits and assay acceptance criteria apply to the stated grade and intended use? boundary
Storage and degradation
Relates sample form and exposure history to validated stability evidence.
Retained integrity
Assesses stability for the actual dry material or solution rather than assigning a universal shelf life to oxytocin.
- What temperature, light, pH where applicable, container and handling history has this material experienced? provenance
- Which stability data support retained identity and potency for this form over the proposed storage or use period? measurement
- Does an excursion or observed degradation require retesting, quarantine or disposal under the applicable procedure? action
Use eligibility and handling Determines what a particular oxytocin material is documented as suitable for and where further decisions belong.
Research reagent identity does not establish medicinal suitability, and substance-level evidence cannot determine patient-specific administration.
Grade and regulatory context
Connects the material to applicable specifications and jurisdiction-specific use constraints.
Documented use status
Requires evidence for claimed grade and eligibility, with finished-product authorisation represented separately.
- Which certificate, specification or pharmacopoeial standard supports the claimed oxytocin grade? provenance
- Which jurisdiction and intended use determine the applicable requirements, and which apply to the finished product instead of the substance? boundary
Handling and action boundaries
Uses preparation-specific hazard evidence and establishes when a specialised model must govern an action.
Evidence-gated actions
Connects proposed handling or use to documented hazards, material suitability and appropriate decision authority.
- Which current safety data and applicable hazard classification cover this exact oxytocin material or preparation? provenance
- What handling, exposure-response and disposal procedures apply to its concentration and physical form? action
- Does the proposed action require a medicinal-product, clinical or research-protocol model before it can proceed? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This describes the oxytocin molecule; endogenous and synthetic denote origin, not different molecular species.
- Identifiers and structural properties are recalled without source verification; current pharmacopoeial requirements and product-specific regulatory details need checking.
- Claims about trust, bonding, or therapeutic psychiatric effects require careful qualification; behavioral effects depend on context, and peripheral concentrations do not straightforwardly establish brain activity.
- Which of these check these first hold for the sense of oxytocin this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Endogenous oxytocin
- Synthetic oxytocin
- Which of these kinds and varieties hold for the sense of oxytocin this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- CAS Registry Number - 50-56-6 - Identifies oxytocin; salts and pharmaceutical preparations require additional specification.
- Molecular formula - C43H66N12O12S2 - Formula of the oxytocin molecule, excluding counterions and water of hydration.
- Amino-acid sequence - CYIQNCPLG-NH2 - Nine residues with a disulfide bond between cysteines at positions 1 and 6 and an amidated C-terminus.
- Which of these identifiers and schemes hold for the sense of oxytocin this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- United States Pharmacopeia-National Formulary, issued by the United States Pharmacopeial Convention, provides quality monographs for oxytocin and oxytocin injection.
- European Pharmacopoeia, published by the European Directorate for the Quality of Medicines & Health, provides an oxytocin quality monograph.
- World Health Organization international biological reference standards support the expression and comparison of oxytocin potency.
- Which of these standards and regulation hold for the sense of oxytocin this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- An endogenous signal supporting uterine contractions during childbirth.
- An endogenous signal causing milk ejection through contraction of mammary myoepithelial cells.
- A pharmaceutical active ingredient used for induction or augmentation of labor.
- A pharmaceutical active ingredient used to prevent or treat postpartum bleeding associated with inadequate uterine contraction.
- A research reagent for studying peptide receptors, neuroendocrine signaling, and social behavior.
- Which of these real-world use hold for the sense of oxytocin this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Molar mass - Approximately 1007.19 - g/mol
- Peptide chain length - 9 - amino-acid residues
- Intramolecular disulfide bonds - 1 - bond per molecule
- Which of these typical measurements hold for the sense of oxytocin this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Excessive pharmaceutical stimulation of the uterus can compromise fetal oxygenation and cause serious maternal injury.
- Rapid intravenous administration can cause hypotension and cardiovascular disturbances.
- Prolonged administration, particularly with excessive electrolyte-free fluid, can contribute to water intoxication and hyponatremia.
- Peptide degradation during unsuitable storage can reduce pharmaceutical potency.
- Confusing biological potency units with mass or solution volume can cause medication errors.
- Which of these failure modes and hazards hold for the sense of oxytocin this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Approved indications, formulations, labeling, and administration requirements differ between national medicines regulators.
- Applicable pharmacopoeial specifications and product storage requirements depend on jurisdiction and formulation.
- Which of these regional variation hold for the sense of oxytocin this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Vasopressin - A related nonapeptide with a different amino-acid sequence, principally associated with water balance and vascular effects.
- Carbetocin - A distinct synthetic oxytocin analogue with structural modifications and a longer duration of action.
- Prolactin - A protein hormone that principally supports milk production; oxytocin triggers milk ejection.
- Oxytocin injection - A finished pharmaceutical formulation containing oxytocin plus a vehicle and potentially other ingredients, rather than the substance alone.
- Oxytocin receptor - The receptor protein that responds to oxytocin, rather than the peptide ligand.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of oxytocin this model covers, and on what evidence? provenance
What the second pass must settle
- Which authoritative identifier records should anchor this entry, and how should salts, hydration and peptide-content reporting be represented without creating duplicate substance models?
- Which analytical and biological reference methods provide sufficiently comparable oxytocin measurements across manufactured material and biological matrices?
- Which form-specific physical constants, solubility and degradation data are reliable, and should decomposition behaviour replace melting or boiling values where those values are not meaningful?
- Which current pharmacopoeial specifications, hazard classifications and occupational exposure provisions apply to the intended grades and jurisdictions?
- How strongly do available studies support inferences between peripheral measurements, central activity and behavioural outcomes, and where must those links remain unresolved?